March 1 (Reuters) - Imv Inc ::IMV INC ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS OFFERING OF 4.90 MILLION COMMON SHARES PRICED AT C$5.45PER SHARE.INTENDS TO USE NET PROCEEDS OF OFFERING TO ACCELERATE DEVELOPMENT OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA.
Full Article
Aug 9 (Reuters) - Imv Inc ::IMV INC. REACHES MULTIPLE MILESTONES IN ADVANCED OVARIAN CANCER CLINICAL TRIAL.IMV INC - EXPECTS TO RELEASE TOPLINE DATA FROM PHASE 1B ARMS OF STUDY BY END OF 2018.
Full Article
May 14 (Reuters) - Imv Inc ::IMV INC. (FORMERLY IMMUNOVACCINE INC.) ANNOUNCES Q1 2018 FINANCIAL RESULTS.IMV INC - QTRLY LOSS PER SHARE $0.7.
Full Article
April 24 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER.IMMUNOVACCINE - COS PLAN TO ADD PHASE 2 COMPONENT TO ONGOING PHASE 1B STUDY OF DXP-SURVIVAC WITH INCYTE'S EPACADOSTAT AND LOW DOSE CYCLOPHOSPHAMIDE.IMMUNOVACCINE - PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL.IMMUNOVACCINE INC - EXPECTS TO PROVIDE A CLINICAL UPDATE ON PHASE 1B PROGRAM IN FIRST HALF OF 2018.
Full Article
Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVACDEMONSTRATE TOLERABLE SAFETY PROFILE.
Full Article
Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share $0.02.
Full Article
Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.
Full Article
Earnings vs. 
Estimates